Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.

Aug 7, 2022 Aug 7, 2022 Updated Aug 7, 2022 LOUISVILLE, Ky. (WDRB) -- “To always have hope no matter what comes up, you can either choose fear or hope, and I feel like hope is always the best option.” ...

Credit: Thinkstock. The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS. The Food and Drug Administration (FDA) has approved Tecentriq ...

Alveolar soft part sarcoma (ASPS) remains one of the rare and enigmatic soft tissue malignancies, principally affecting adolescents and young adults. Despite its low incidence, recent research has ...

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology Alveolar soft part sarcoma (ASPS) is a rare, highly ...

Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic ...

image: Left frame: Normally, tumor cells (purple) evade the immune system’s T cells (pink) by expressing a checkpoint protein known as PD-L1. Right frame: Atezolizumab (Tecentriq) binds to PD-L1 and ...